PT-141 (Bremelanotide) Research Peptide: Mechanism, Melanocortin Pharmacology & Handling

PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide studied as an agonist of the melanocortin receptor system, primarily the melanocortin-4 receptor (MC4R) and melanocortin-3 receptor (MC3R). It is a structural analog of alpha-melanocyte-stimulating hormone (alpha-MSH) and is used in laboratory research to probe central melanocortin signaling. This article summarizes the mechanism, the published research record, and standard handling considerations. It is intended strictly for in-vitro and laboratory research context and is not guidance for human or animal use.

What Is PT-141 (Bremelanotide)?

PT-141 is a cyclic seven-amino-acid peptide from the melanocortin peptide family. It is an active metabolite of Melanotan II and was characterized as a melanocortin-receptor agonist for research into central nervous system signaling pathways (Molinoff 2003). Unlike agents that act on peripheral vascular tissue, PT-141 is studied as a centrally acting probe of the melanocortin circuitry in the hypothalamus and related brain regions.

Its cyclic structure improves stability relative to linear melanocortin peptides, which makes it a useful tool compound for characterizing receptor binding and downstream signaling in cell-based and animal models.

Mechanism of Action

The melanocortin system consists of five G-protein-coupled receptors (MC1R through MC5R) and endogenous ligands derived from proopiomelanocortin (POMC). PT-141 binds and activates MC3R and MC4R, receptors expressed heavily in the central nervous system, including the hypothalamus (Molinoff 2003).

When a melanocortin agonist binds MC4R, the receptor couples to the Gs protein and raises intracellular cyclic AMP (cAMP), triggering downstream signaling. Structural biology has clarified this activation: cryo-electron microscopy of the human MC4R in its active, Gs-coupled state with melanocortin agonists has mapped the ligand-binding pocket at near-atomic (~3 angstrom) resolution, revealing the molecular basis of ligand recognition and receptor activation (MC4R-Gs structural study 2021). These structures provide a framework for understanding how cyclic melanocortin analogs such as PT-141 stabilize the active receptor state.

Downstream of MC4R activation in central circuits, the melanocortin pathway has been linked in pharmacological studies to nitrergic signaling and neuronal nitric oxide release (Molinoff 2003). This central mechanism is what distinguishes melanocortin research tools from peripherally acting compounds studied in overlapping physiological domains.

Published Research Overview

The research record on PT-141 spans receptor pharmacology, structural biology, in-vitro cell studies, and human clinical pharmacology conducted during its development. Early characterization described it as "a melanocortin agonist," detailing its receptor selectivity and pharmacological profile (Molinoff 2003). A broader review placed it within the history of melanocortin peptide therapeutics, tracing milestones from alpha-MSH analogs through clinical candidates and noting that PT-141 derives from the cyclic peptide Melanotan II (Hadley & Dorr 2006).

Clinical pharmacology studies characterized the compound's kinetics. A double-blind, placebo-controlled evaluation of intranasal PT-141 reported a median time-to-maximum concentration of about 0.5 hours and a mean half-life of roughly 1.85 to 2.09 hours (Diamond 2004). Separate placebo-controlled work characterized the melanocortin-receptor-agonist profile in additional populations (Diamond 2006). These reports are cited here as the historical scientific record; they do not constitute use recommendations, and the material supplied by Dynamite Research Peptides is for laboratory research only.

More recent in-vitro work illustrates how PT-141 is used as a receptor probe today. A 2024 cell-based study reported that bremelanotide reduced expression of the anti-apoptotic protein survivin and induced cell death in human glioblastoma cell lines at concentrations that were not toxic to normal human cells; both effects were abolished by a melanocortin-3/4 receptor antagonist and by forced over-expression of survivin, supporting an MC3R/MC4R-dependent, survivin-linked mechanism (in-vitro glioblastoma study 2024). This kind of controlled cell-culture experiment is representative of the research-use context for the compound.

How PT-141 Differs From Melanotan II

PT-141 is an active metabolite and analog of Melanotan II, but the two are studied for different purposes. Melanotan II is a broader melanocortin agonist with notable activity at MC1R, the receptor associated with melanin production. PT-141 is comparatively more focused on the MC3R/MC4R axis relevant to central signaling research, which is why it is used as a more selective tool compound for studies of the hypothalamic melanocortin circuit (Hadley & Dorr 2006).

Frequently Asked Questions

What receptors does PT-141 target? PT-141 acts as an agonist primarily at the melanocortin-4 receptor (MC4R) and melanocortin-3 receptor (MC3R), both concentrated in the central nervous system (Molinoff 2003).

Is PT-141 the same as bremelanotide? Yes. PT-141 is the research designation and bremelanotide is the nonproprietary name for the same cyclic heptapeptide melanocortin agonist.

How does PT-141 relate to Melanotan II? PT-141 is an active metabolite of Melanotan II, with a pharmacological profile shifted toward the MC3R/MC4R axis rather than the MC1R-linked pigmentation pathway (Hadley & Dorr 2006).

What purity does Dynamite Research Peptides provide? Our PT-141 is 99%+ purity with a Certificate of Analysis available for every batch.

Storage & Handling

PT-141 is supplied as a lyophilized (freeze-dried) powder. Store it at -20 degrees C or below, protected from light and moisture. Reconstitute only with an appropriate sterile solvent immediately before laboratory use, keep reconstituted material refrigerated, and avoid repeated freeze-thaw cycles, which can degrade peptide integrity.

Research Note (Updated July 2026)

As of 2026, the melanocortin system remains an active area of structural and cell-biology research, and recent in-vitro studies (through 2024) continue to use bremelanotide as an MC3R/MC4R-selective probe (in-vitro glioblastoma study 2024). This article reflects the peer-reviewed record available at the time of update.

All products are for research use only — not for human or animal consumption. Nothing here is medical advice or a therapeutic, dosing, or human-use recommendation.